Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 4Neuroblastoma 4Head and Neck Neoplasms 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Lymphoma 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms 2Mouth Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hodgkin Disease 2Burkitt Lymphoma 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1

Interventions

Peripheral Blood Stem Cell Transplantation 38fludarabine phosphate 36Cyclophosphamide 31Mycophenolic Acid 28Cyclosporine 25Whole-Body Irradiation 24Tacrolimus 22Busulfan 18Antilymphocyte Serum 18Radiotherapy 16Methotrexate 16Filgrastim 14Etoposide 13Methylprednisolone 10Lenalidomide 10Bortezomib 10Vorinostat 9Melphalan 9Flow Cytometry 9Rituximab 8Gemcitabine 8Cord Blood Stem Cell Transplantation 7Bexarotene 7pembrolizumab 6mogamulizumab 6Alemtuzumab 6tanespimycin 5fludarabine 5aldesleukin 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sezary Syndrome × Fenretinide × Clear all
NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

SciTech Development, Inc.

Phase 1 Recruiting
46 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡